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ABSTRACT
Corona Virus Disease 2019 (COVID-19) is a worldwide pandemic with a high mortality rate
(2% to 5%) and a high infectivity compared with previous known viral respiratory illness. Data has
shown that medical personnel were infected more than other people. Therefore, health care providers had to establish new protocols that balance between health care providers’ protection and patients’ benefit, and guarantee the availability of medical resources in cases of emergency. This article presents several recommendations and protocols for invasive management of coronary artery
disease in our region during the COVID-19 pandemic especially after the recent increase in the
number of cases in our region. We expect that these recommendations will help protect medical
personnel in cardiology field from the high risk of infection of COVID-19, and eventually this
would keep the cardiology team available in case of emergency. In addition, they will provide safe
and effective management of patients with coronary artery disease during this pandemic.
Keywords: COVID-19; Coronary artery disease, acute coronary syndrome, STEMI, PCI.
INTRODUCTION
Corona Virus Disease 2019 (COVID-19)
is a global pandemic that is caused by the
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)[1, 2]. It is a highly
contagious virus which puts an enormous
strain on the healthcare providers. The total
global number of COVID-19 cases has surpassed 1 million with over 40,000 mortalities
in 4 April 2020 [3]. In Palestine and Jordan,
the number of cases has been increasing
since the first case was confirmed in the beginning of March 2020. The total number in
Palestine was over 100 cases at the time of
writing this report (about 23 cases per 1 million of population), while it exceeded 250
cases in Jordan (about 26 cases per 1 million
of population)[3]. Data showed that the number of health care providers who were infected by COVID-19 was higher than the number
of infected workers in different sectors. For

instance, 3300 health care workers in China
were infected by COVID-19 by the beginning of March 2020, and 20% of health care
providers were infected in Italy [4, 5].
Impact of COVID-19 on cardiovascular patients
Acute cardiac injury - which is defined
as elevated troponin >99th percentile, and
new abnormalities in electrocardiogram
(ECG) and Echo - was found in 12-19 % of
patients with COVID-19 infection. Acute
cardiac injury is seen more in patients with
comorbidities like hypertension (HTN), diabetes mellitus (DM), coronary heart disease
(CHD) (10 % of total patients had CHD), and
cerebrovascular disease (CVD). It also carries higher risk of mortality among this type
of patients.[1, 6].
As COVID-19 is a highly contagious
disease, invasive treatment for coronary artery disease became more risky and challeng-
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ing. Therefore, cardiac societies in different
regions in the world have published new recommendations for the management of coronary artery disease patients to balance between the benefit of management and the risk
of COVID-19 infection [7, 8]. China and the
United States published their experience in
this field which mainly pointed toward the
following: to avoid elective cases, to avoid
entering suspected patient with COVID-19 to
the catheterization laboratory as much as
possible, to prepare the team with maximum
personal protective equipment (PPE) when
percutaneous coronary intervention (PCI) is
necessary, and to perform the procedure in an
isolated room. It has also been emphasized
that PCI was considered only in selected cases like ST elevation myocardial infarction
(STEMI) with contraindication to thrombolysis, or myocardial infarction (MI) with hemodynamic instability and fatal arrhythmia
[9-11].
It should be mentioned that these recommendations were provided for countries
with high prevalence of COVID-19. However, prevalence in our region is increasing day
after day.
Mortality in myocardial infarction
Myocardial infarction (MI) is considered
the leading cause of death worldwide.[12]
However, with the improvement in the management strategies including percutaneous
coronary intervention (PCI) and thrombolysis, mortality due to MI has gradually decreased over the last decades. Despite this
improvement, myocardial infarction is still
responsible for one third of all deaths around
the world.
The reported overall 30-day mortality
after myocardial infarction is around 5%.[13]
Higher rate of morality was reported in
STEMI (up to 10%) compared with non-ST
elevation myocardial infarction (NSTEMI)
(about 2%). [13, 14] The reported rate of
mortality (30-day mortality rate) among patients with STEMI varies according to the
type of management strategy, it is 13% with
medical therapy alone, 6-7% with optimal
use of thrombolysis,[15] and only 3-5 % if
PCI performed according to the guidelines
[16, 17].

Regarding NSTEMI patients, invasive
management has almost a close rate of mortality in short and long term compared to
conservative management despite the fact
that invasive strategy reduced recurrent
MI.[18] On the other hand, a recent metaanalysis showed that invasive management
could reduce mortality in high risk NSTEMI
patient.[19].
Mortality of MI According to the Infarcted
Related Artery
Right coronary artery (RCA) and left
circumflex artery (LCX) were the most
common infarct related artery in STEMI and
NSTEMI (49.9% and 48.4% respectively).
The highest infarct related artery mortality
was related to total occlusion of left anterior
descending artery (LAD) (reached 19 % over
36 months) followed by LCX (16% over 36
months) and lastly RCA (11 % over 36
months). In patients with NSTEMI, mortality
was comparable between patient with total
occlusion and non-total occlusion. It was
higher in LCX artery occlusion (around 16%
over 36 months) followed by LAD and RCA
(both around 12%) [20].
Rules for cardiac procedures and interventions in COVID-19 pandemic
As it was mentioned earlier, COVID-19
is an extremely contagious infection with
serious impact on cardiovascular patients and
health care workers in cardiology field.
Hence, a group of interventional cardiologists, ICU specialists and internists from Palestine and Jordan have discussed this issue
through the different means of social media.
They came up with several recommendations
based on their expertise and the review of
available relevant literature in order to be
sure of giving patients with coronary artery
disease the benefit and best practice without
compromising their safety and the safety of
the hospital staff during the utilization of
catheterization laboratory.
Safety Measures inside the Catheterization
laboratory
1.

All patients entering the catheterization
laboratory should wear surgical face
mask.
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2.

3.

4.

Radial approach is preferred over femoral because of longer face to radial distance and less time of staff contact for
homeostasis.
No running nurse is needed in the catheterization laboratory to avoid the in- and
out- from the catheterization laboratory,
doors must be closed and no doors open
between catheterization laboratory and
monitoring area.

tation. This should be based on clinical
judgment to avoid any harmful effects.
3.

Avoid complex intervention in patients
with stable ischemic heart disease (left
main, chronic total occlusion, complex
bifurcation) as they may require urgent
Coronary artery bypass grafting (CABG)
in case of complication.

4.

Delay elective structural cardiac intervention:

Cardiac catheterization laboratory staff
should be divided into team A and team
B to limit the number that is needed to
be isolated in case of contact with
COVID-19 patients.

a. Transcatheter aortic valve implantation (TAVI) should be delayed unless severe decompensated aortic
stenosis (AS), e.g. causing severe
heart failure.

Elective procedures
Due to SARS-CoV-2 pandemic which
has placed a huge burden on the healthcare
system, many hospitals around the world
have decided to delay elective cardiac intervention during the COVID-19 pandemic.
This step aims to save resources and to decrease the exposure of patients to the hospital
environment where the chance to get infected
with COVID-19 might be higher than anywhere else, in addition to decrease the risk of
staff to acquire this potentially serious infection.
Therefore, we recommend the following:
1.

Avoid elective procedures for patients
with multiple comorbidities or patients
who may require long stay in the hospital in order to maintain hospital beds
available.

2.

Delay the elective cardiac procedures or
intervention for stable ischemic heart
disease with non-life-threatening presen-

b. All Mitral Clip and Left atrial appendage closure procedures should
be delayed.
5.

Delay CABG surgery as it needs more
staff, more ventilators and more ICU
beds.

6.

Transesophageal Echo (TEE) procedure
should be avoided due to high risk of infected droplet exposure.

Acute Coronary Syndrome (ACS)
All Acute Coronary Syndrome (ACS)
patients should be tested for COVID-19 if
test is available. However, this is a debatable
subject in our region since the access to rapid
testing is very limited. Therefore, it requires
clinical judgment that is based on clinical
symptoms and epidemiological [11, 21-23]
history to define patients at high risk for
COVID-19 infection as clarified in Table 1.

Table (1): Patients’ clinical assessment for COVID-19 infection.
A. Confirmed case of
COVID-19
B. Probable case of
COVID-19
C. High risk for
COVID-19

A confirmed case is a person with laboratory confirmation of infection with the COVID-19 virus, irrespective of clinical signs and
symptoms.
✓A case for whom the report from laboratory testing for the COVID-19
virus is inconclusive.
✓ A patient with acute respiratory illness (that is, fever and at least
one sign or symptom of respiratory disease, for example, cough or
shortness of breath)
AND
✓ No other etiology that fully explains the clinical presentation
AND
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✓ A history of travel to or residence in a country area or territory
that has reported local transmission of Corona Virus Disease-19
(COVID-19) during the last 14 days prior to symptom.
 A patient with any acute respiratory illness
AND
 Who has been a contact of a confirmed or probable case of COVID19 during the last 14 days prior to the onset of symptoms.
 A person with a history of travel to or residence in a country area or
D. Intermediate risk
territory that has reported local transmission of Corona Virus Disfor COVID-19
ease-19 (COVID-19) during the last 14 days.
OR
 Who has been at contact with confirmed or probable case of COVID19 during the last 14 days.
AND
 No symptoms of acute Respiratory illness.
 No symptoms of acute respiratory illness
E. Low risk for
COVID-19
AND
 No history of travel to or residence in a country area or territory that
has reported local transmission of Corona Virus Disease-19 (COVID19)
AND
 Contact confirmed or probable case of COVID-19 during the last 14
days.
should only be performed to the
A. ST elevation Myocardial (STEMI) paculprit vessel unless a non-culprit
tients
lesion is deemed unstable or multiFor patients with STEMI (Table 2), we
ple culprit lesions are present.
recommend the following Figure 1:
Table (2): Conditions in which PCI is con1. All patients should have an ECG with
sidered for patients with STEMI.
extended leads (V7-V9, V4R-V6R) to
exclude right ventricular and posterior
infarction.
2.

All patients with confirmed or probable
COVID-19 or at high to intermediate
risk for COVID-19 should be managed
in a way that preserves balance between
staff exposure and patients’ benefit as
follows:
a.

Thrombolysis is considered a good
option for stable low risk STEMI
patient (e.g. inferior STEMI without
right ventricular involvement or lateral myocardial infarction without
hemodynamic compromise) when
they present within 12 hours, and no
contraindication to thrombolysis.

b.

PCI is considered in certain conditions after applying maximum protection to prevent staff exposure including effective personal protective
equipment (PPE). Moreover, PCI

All the above recommendations are not
applied if risks are more than benefits such as
COVID-19 pneumonia, in this case the patient will be treated with thrombolysis in the
Cardiac Care Unit (CCU). If successfully reperfused (pain relief, ST resolution > 50 %,
reperfusion arrhythmia), elective PCI will be
considered after recovery from COVID-19
infection. The need for terminal cleaning is
highly required after procedures on suspected
or known COVID-19 patients. Therefore,
these cases should be done at the end of the
working day if possible. Moreover, the re-
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striction of cases to a dedicated cath laboratory would be of value if that is possible.
c.

When thrombolysis is contraindicated or
beyond reperfusion window and the PCI
can’t be performed due to high risk on
staff, patients will be treated conservatively in the CCU (Antiplatelet, antico-

agulation for 48 hrs, high intensity statin,
B-Blockers/ACE-inhibitors as tolerated).
3.

Patients with low risk for COVID 19
should be managed with PCI if hospital
resources and capabilities allowed, otherwise thrombolysis will be considered
when indicated.

Figure (1): Management algorithm for patient with STEMI during COVID -19 pandemic. STEMI:
ST segment elevation myocardial infarction, COVID-19: Corona-virus disease 2019, PCR: Polymerase chain reaction, PCI: Percutaneous coronary intervention.
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low risk NSTE-ACS patient.
b. Early Angiography (<2hrs) Can be
considered in high risk NSTE-ACS:

B. Non ST-Elevation Acute Coronary
Syndrome (NSTE-ACS)
For most patients with NSTE-ACS and
suspected COVID-19, time usually allows for
screening for COVID-19 before cardiac catheterization, in addition to more infection control measure that can be applied.
With respect to the above mentioned, we
suggest the following (Figure 2):
1. All NSTE-ACS patients should have
extended leads ECG (V7-V9) to exclude
LCX occlusion.
2. Patients with confirmed or probable
COVID-19 or at high to intermediate
risk for COVID-19 should be managed
in a way that preserves balance between
staff exposure and patients’ benefit as
follow:
a. A conservative management (Antiplatelet, anticoagulation for 48 hrs,
high intensity statin, B-Blockers/
ACE-inhibitors) is considered a
good option for the relatively stable




3.

Refractory chest pain
Cardiogenic Shock
Life threatening arrhythmia

Patients with low risk for COVID 19 can
be managed as follow:
a. Admit to CCU for Conservative
management (Antiplatelet, anticoagulation for 48 hrs., high intensity
statin, B-Blockers/ACE-inhibitors)
b. Consider Angiography (within 24
hrs.) for high risk NSTE-ACS
(GRACE score > 140, dynamic ST
segment changes, significant rise
and fall of troponin) if hospital resources allow.

It should be noted that patients with
NSTE-ACS should be discharged immediately after angiography in order to maximize
bed availability and to reduce patients’ exposure within the hospital.

Figure (2): Management algorithm for patient with NSE-ACS during COVID -19 pandemic. NSTACS: Non ST segment elevation acute coronary syndrome, COVID-19: Corona-virus disease 2019,
PCR: Polymerase chain reaction, PCI: Percutaneous coronary intervention.
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tion until definitive airway is secured.

Intubation and CPR in COVID-19 patients
When dealing with cardiac arrest in patients with COVID-19, intubation and CPR
will cause aerosolization of respiratory secretions. This will increase the possibility of
exposure to personnel. Therefore, Intubation
of patients before arrival to cardiac catheterization will reduce the risk of staff exposure
to patients’ secretion.
With reference to the above, in suspected
or confirmed COVID-19, we recommend:
1.

Intubate patients who need to be intubated before arrival to the cardiac catheterization.

2.

Consider the following if intubation is a
must inside the cardiac catheterization:
a.

3.

Personnel number should be minimized in order to decrease the staff
exposure.

b.

Rapid Sequence Intubation (RSI) by
professional
trained
personnel
should be done in order to improve
success and decrease exposure time.

c.

Bag valve mask ventilation (BVM)
should not be allowed. ET tube
should be inserted quickly and successfully from the first attempt.

Take these recommendations into account if cardiopulmonary resuscitation
(CPR) is required in COVID-19 patients:
a.

e.

Defibrillate as soon as possible if
the patient has shockable rhythm
(Ventricular Fibrillation /Ventricular
tachycardia). Chest Bad should be
used if available.

f.

During CPR, air way management
should be done as follows:


Start with Rapid Sequence Intubation as soon as you can to
minimize aerosolization in case
the patient does not have a
shockable rhythm.



Provide oxygen through a nonrebreather face mask at 15L/min
before securing a definitive airway.



Reduce aerosolized virus by
avoiding BVM ventilation,
high-flow nasal cannula, and
non-invasive ventilation (CPAP,
BiPAP)



Put a surgical face-mask and a
blanket over the patient’s face
before starting chest compressions if passive oxygen is not
available.



Consider Laryngeal Mask Airway (LMA) when pauses in
chest compressions are excessive and ET tube insertion is
difficult.



Keep the Code Blue Team away
from the head of the bed during
the intubation.

Use Personnel protective equipment
(PPE) including:


N95 respirator, face shield,
gown and gloves be used by all
code responders during code
events



Place surgical mask on the patient's face.

b.

Reduce the number of staff in the
CPR proximity.

c.

An automated compression device
“Lucas device” should be used if
available.

d.

CPR should be done by chest compression-only without BVM ventila-

Conclusions and Recommendations
COVID 19 is a pandemic disease with
high contagious rates that affected around 1
million populations all over the world. The
high contagious rates of this serious infection
as well as the excessive mortality rates have
overwhelmed the health care sector and have
emplaced a huge burden on medical resources. This paper provides scientific evidence in addition to expert opinion on safe
practice of cardiovascular medicine in Palestine and Jordan (including invasive cardiolo-
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gy intervention for coronary artery disease)
during the pandemic period with consideration of the prevalence of the disease in our
region.
Our recommendations emphasize on
testing every patient with acute coronary
syndrome (ACS) for COVID-19 if possible,
or categorizing patients into low, intermediate or high risk if testing is not available with
specific recommendations according to each
category and patients presentation. The recommendations also focus on avoiding elective procedures during the pandemic and taking specific precautions if invasive intervention is mandatory. It should be mentioned
that these recommendations are time limited
and only applicable to the pandemic period.
The previous recommendations, however,
would be applied again once the pandemic is
over.
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